Tim Rendell1, Julie Barnett2, Sion Scott3, David Wright3. 1. University of Bath, Claverton Down, Bath, BA2 7AY, UK. tcr36@bath.ac.uk. 2. University of Bath, Claverton Down, Bath, BA2 7AY, UK. 3. University of Leicester, University Rd, Leicester, LE1 7RH, UK.
Abstract
BACKGROUND: Pharmacogenomics is a novel arena of medicine that uses patients' Deoxyribonucleic Acid to support pharmacists and prescribers selecting the most appropriate medicine for patients. AIM: To review and validate a service specification for a pharmacogenomics testing service. METHOD: Consensus methods (Delphi method and the Nominal Group Technique) were deployed. A consensus panel comprising of pharmacists, prescribers and patients was convened to participate in the co-design process. Panel members were first surveyed to obtain their views on Behaviour Change Techniques identified as necessary for the service in a previous study. Following this, a workshop was convened to discuss, agree and confirm details for the service specification and recommend strategies for operationalisation. Outputs from the workshop were used to inform a final version of the service specification. RESULTS: From the consensus panel (pharmacists (n = 6), general practitioners (n = 3) and patients (n = 3)), strategies for operationalisation of nine Behaviour Change Techniques were agreed as being required. In addition, several unique and innovative strategies for implementation of the community pharmacy service were identified and included in the service specification. CONCLUSION: The research shows that to encourage community pharmacist engagement in providing a pharmacogenomic testing service and prescriber acceptance of recommendations for any changes to patients' prescriptions, a multi-professional launch event is required. To agree communication strategies and professional boundaries, training in clinical decision making and patient support materials are required as is guidance on how to deliver the service in a standardised manner. Finally, healthcare professionals would be reassured by the provision of an expert help-line for any complex patients.
BACKGROUND: Pharmacogenomics is a novel arena of medicine that uses patients' Deoxyribonucleic Acid to support pharmacists and prescribers selecting the most appropriate medicine for patients. AIM: To review and validate a service specification for a pharmacogenomics testing service. METHOD: Consensus methods (Delphi method and the Nominal Group Technique) were deployed. A consensus panel comprising of pharmacists, prescribers and patients was convened to participate in the co-design process. Panel members were first surveyed to obtain their views on Behaviour Change Techniques identified as necessary for the service in a previous study. Following this, a workshop was convened to discuss, agree and confirm details for the service specification and recommend strategies for operationalisation. Outputs from the workshop were used to inform a final version of the service specification. RESULTS: From the consensus panel (pharmacists (n = 6), general practitioners (n = 3) and patients (n = 3)), strategies for operationalisation of nine Behaviour Change Techniques were agreed as being required. In addition, several unique and innovative strategies for implementation of the community pharmacy service were identified and included in the service specification. CONCLUSION: The research shows that to encourage community pharmacist engagement in providing a pharmacogenomic testing service and prescriber acceptance of recommendations for any changes to patients' prescriptions, a multi-professional launch event is required. To agree communication strategies and professional boundaries, training in clinical decision making and patient support materials are required as is guidance on how to deliver the service in a standardised manner. Finally, healthcare professionals would be reassured by the provision of an expert help-line for any complex patients.
Authors: Ivan R Diamond; Robert C Grant; Brian M Feldman; Paul B Pencharz; Simon C Ling; Aideen M Moore; Paul W Wales Journal: J Clin Epidemiol Date: 2014-04 Impact factor: 6.437
Authors: Susan Michie; Michelle Richardson; Marie Johnston; Charles Abraham; Jill Francis; Wendy Hardeman; Martin P Eccles; James Cane; Caroline E Wood Journal: Ann Behav Med Date: 2013-08
Authors: Cathelijne H van der Wouden; Paul C D Bank; Kübra Özokcu; Jesse J Swen; Henk-Jan Guchelaar Journal: Genes (Basel) Date: 2019-05-29 Impact factor: 4.096
Authors: Marie Johnston; Rachel N Carey; Lauren E Connell Bohlen; Derek W Johnston; Alexander J Rothman; Marijn de Bruin; Michael P Kelly; Hilary Groarke; Susan Michie Journal: Transl Behav Med Date: 2021-05-25 Impact factor: 3.046